177 related articles for article (PubMed ID: 37517031)
1. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
Zhang Z; Wu H; Shen C; Zhou F
Biochem Genet; 2024 Apr; 62(2):1021-1039. PubMed ID: 37517031
[TBL] [Abstract][Full Text] [Related]
2. Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Hamm CA; Moran D; Rao K; Trusk PB; Pry K; Sausen M; Jones S; Velculescu VE; Cristofanilli M; Bacus S
Mol Cancer Ther; 2016 Jul; 15(7):1746-56. PubMed ID: 27196778
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.
Bertucci F; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; Van Dam P; Woodward WA; Cristofanilli M; Reuben JM; Dirix L; Viens P; Symmans WF; Birnbaum D; Van Laere SJ
Ann Oncol; 2014 Feb; 25(2):358-65. PubMed ID: 24299959
[TBL] [Abstract][Full Text] [Related]
4. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer.
Remo A; Simeone I; Pancione M; Parcesepe P; Finetti P; Cerulo L; Bensmail H; Birnbaum D; Van Laere SJ; Colantuoni V; Bonetti F; Bertucci F; Manfrin E; Ceccarelli M
J Transl Med; 2015 May; 13():138. PubMed ID: 25928084
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity.
Rypens C; Marsan M; Van Berckelaer C; Billiet C; Melis K; Lopez SP; van Dam P; Devi GR; Finetti P; Ueno NT; Bertucci F; Dirix P; Neven P; Vermeulen P; Dirix L; Van Laere SJ
Breast Cancer Res Treat; 2020 Apr; 180(2):385-395. PubMed ID: 32043194
[TBL] [Abstract][Full Text] [Related]
6. Genomic and expression analysis of microdissected inflammatory breast cancer.
Woodward WA; Krishnamurthy S; Yamauchi H; El-Zein R; Ogura D; Kitadai E; Niwa S; Cristofanilli M; Vermeulen P; Dirix L; Viens P; van Laere S; Bertucci F; Reuben JM; Ueno NT
Breast Cancer Res Treat; 2013 Apr; 138(3):761-72. PubMed ID: 23568481
[TBL] [Abstract][Full Text] [Related]
7. Screening and Identification of Key Biomarkers in Inflammatory Breast Cancer Through Integrated Bioinformatic Analyses.
Wu J; Lv Q; Huang H; Zhu M; Meng D
Genet Test Mol Biomarkers; 2020 Aug; 24(8):484-491. PubMed ID: 32598242
[No Abstract] [Full Text] [Related]
8. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Cervera N; Tarpin C; Nguyen C; Xerri L; Houlgatte R; Jacquemier J; Viens P; Birnbaum D
Cancer Res; 2005 Mar; 65(6):2170-8. PubMed ID: 15781628
[TBL] [Abstract][Full Text] [Related]
10. Identification of genes and critical control proteins associated with inflammatory breast cancer using network controllability.
Wakai R; Ishitsuka M; Kishimoto T; Ochiai T; Nacher JC
PLoS One; 2017; 12(11):e0186353. PubMed ID: 29108005
[TBL] [Abstract][Full Text] [Related]
11. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
13. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
[TBL] [Abstract][Full Text] [Related]
14. IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages.
Mohamed HT; El-Husseiny N; El-Ghonaimy EA; Ibrahim SA; Bazzi ZA; Cavallo-Medved D; Boffa MB; El-Shinawi M; Mohamed MM
Curr Probl Cancer; 2018; 42(2):215-230. PubMed ID: 29459177
[TBL] [Abstract][Full Text] [Related]
15. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
Masuda H; Baggerly KA; Wang Y; Iwamoto T; Brewer T; Pusztai L; Kai K; Kogawa T; Finetti P; Birnbaum D; Dirix L; Woodward WA; Reuben JM; Krishnamurthy S; Symmans W; Van Laere SJ; Bertucci F; Hortobagyi GN; Ueno NT
Breast Cancer Res; 2013 Nov; 15(6):R112. PubMed ID: 24274653
[TBL] [Abstract][Full Text] [Related]
16. Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling.
Allen SG; Chen YC; Madden JM; Fournier CL; Altemus MA; Hiziroglu AB; Cheng YH; Wu ZF; Bao L; Yates JA; Yoon E; Merajver SD
Sci Rep; 2016 Dec; 6():39190. PubMed ID: 27991524
[TBL] [Abstract][Full Text] [Related]
17. miRNome of inflammatory breast cancer.
Maltseva DV; Galatenko VV; Samatov TR; Zhikrivetskaya SO; Khaustova NA; Nechaev IN; Shkurnikov MU; Lebedev AE; Mityakina IA; Kaprin AD; Schumacher U; Tonevitsky AG
BMC Res Notes; 2014 Dec; 7():871. PubMed ID: 25471792
[TBL] [Abstract][Full Text] [Related]
18. MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer.
Manai M; ELBini-Dhouib I; Finetti P; Bichiou H; Reduzzi C; Aissaoui D; Ben-Hamida N; Agavnian E; Srairi-Abid N; Lopez M; Amri F; Guizani-Tabbane L; Rahal K; Mrad K; Manai M; Birnbaum D; Mamessier E; Cristofanilli M; Boussen H; Kharrat M; Doghri R; Bertucci F
Cells; 2022 Sep; 11(18):. PubMed ID: 36139501
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network.
Valeta-Magara A; Gadi A; Volta V; Walters B; Arju R; Giashuddin S; Zhong H; Schneider RJ
Cancer Res; 2019 Jul; 79(13):3360-3371. PubMed ID: 31043378
[TBL] [Abstract][Full Text] [Related]
20. Role of adipose tissue-derived cytokines in the progression of inflammatory breast cancer in patients with obesity.
Ibrahim AS; El-Shinawi M; Sabet S; Ibrahim SA; Mohamed MM
Lipids Health Dis; 2022 Aug; 21(1):67. PubMed ID: 35927653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]